Martin Peter Carroll, MD

Kumar A, Hamane K, Duault C, Lima-Junior JR, Jung DH, Qin H, Salcido S, Huang M, Guo X, Taghi Khani A, Sanchez Ortiz A, Ghoda L, Marcucci G, Lacayo NJ, Sakamoto KM, Hurtz C, Carroll M, Tasian SK, Geng H, Ji L, Armenian S, Izraeli S, Wu X, Maecker HT, Swaminathan S. Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia , Cell Rep Med: 2026

Cao Z, Yu S, Peng J, Barrett DR, Liu Y, Sussman JH, Chen C, Thadi A, Liu L, Alikarami F, Xu J, Carroll MP, Tan K, Bernt KM, Shi J. CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples , Mol Cell, 86: 2026,968-985

Neelamraju Y, Rapaport F, Gandara JA, Paudel BB, DeWolf S, Dunham N, Fan H, Lee T, Mayo MW, Othman J, Sheridan C, Sol-Church K, Solga MD, Wang L, Cripe LD, Dillon R, Kleppe M, Carroll M, Mason CE, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Paietta E, Levine R, Melnick AM, Bekiranov S, Garrett-Bakelman FE. Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients , Leukemia: 2026

Dunham N, Wang Z, Neelamraju Y, Guo Y, Paudel BB, Meydan C, Gandara JA, Abdelmalak FA, Fan H, Hardwick J, Layer JH, Lee T, Maier B, McDonald WH, Patnaik I, Prajapati S, Rapaport F, Sheridan C, Sheynkman G, Zumbo P, Becker MW, Bullinger L, Carroll MP, D'Andrea RJ, Dillon R, Levine RL, Mason CE, Melnick AM, Neuberg DS, Bekiranov S, Zang C, Davé UP, Garrett-Bakelman FE. The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia , Blood Neoplasia, 3: 2025,100186

Buono R, Juarez D, Paul M, Skuli SJ, Wong IB, Tarnekar I, Ying Z, Le I, Wertheim G, Bakayoko A, Kruidenier M, Sebti SM, Konopleva M, Fleischman AG, Jang C, Carroll M, Fruman DA. Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate , bioRxiv: 2025

Mahdavi L, Alikarami F, Goodrow H, Lenard A, Riedel SS, Libbrecht C, Bowser I, Tasian SK, Falkenstein CD, Manning B, Skuli S, Carroll MP, Wertheim G, Cai SF, McGeehan G, Yu S, Shi J, Xie HM, Bernt KM. Upfront Menin-inhibitor resistance in multiply pretreated leukemias , Exp Hematol: 2025

Pottier A, Park S, Lee Y, Liccardo F, Yang H, Park J, Lorant A, Schnekenburger M, Brusa D, Li V, Valente S, Mai A, Skuli SJ, Carroll M, Boettcher S, Sarry JE, Cerella C, Morceau F, Diederich M. TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia , Cancer Lett, 633: 2025,218011

Prajapati SC, Meydan C, Neelamraju Y, Wang Z, Fan H, Dunham N, Dillon R, Gandara JA, Lee T, Sheridan C, Zumbo P, Becker MW, Bullinger L, Carroll MP, D'Andrea RJ, Levine RL, Mason C, Melnick AM, Zang C, Bekiranov S, Garrett-Bakelman FE. CCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemia , bioRxiv: 2025

Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response , Leukemia: 2025

Liu Y, Li Q, Alikarami F, Barrett DR, Mahdavi L, Li H, Tang S, Khan TA, Michino M, Hill C, Song L, Yang L, Li Y, Pokharel SP, Stamford AW, Liverton N, Renzetti LM, Taylor S, Watt GF, Ladduwahetty T, Kargman S, Meinke PT, Foley MA, Shi J, Li H, Carroll M, Chen CW, Gardini A, Maillard I, Huggins DJ, Bernt KM, Wan L. Editor's Note: Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia , Cancer Discov, 15: 2025,1297-1298